Oral Presentations: Abstract Name Authors Presentation ID Presentation Details Effects of evobrutinib, a Bruton』s tyrosine kinase inhibitor, on slowly expanding lesions: an emerg…
Merck Completes Enrolment of Evobrutinib Phase III Clinical Trials Ahead of ECTRIMS 2021
Oral Presentations: Abstract Name Authors Presentation ID Presentation Details Effects of evobrutinib, a Bruton』s tyrosine kinase inhibitor, on slowly expanding lesions: an emerg…